EGFR and lung carcinoma: GM‐protac could induce EGFR degradation under a lower concentration compared to G‐protac, and inhibit HDAC enzyme activity by increasing the acetylation of HDAC substrate histone 3 in osimertinib or almonertinib resistance lung cancer cells H1975‐OR or H1975‐AR cells.